ETFChannel.com
REPH Description — Societal CDMO Inc

Recro Pharma is a contract development and manufacturing organization, solving formulation and manufacturing challenges primarily in small molecule therapeutic development. Co. utilizes its formulation and development knowledge to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for partners who develop and commercialize or plan to commercialize these products. Co. has launched its clinical trials support services capabilities, which includes preparation of clinical trial supplies, as well as services dedicated to the development and Good Manufacturing Practices, of high-potency products.

Company Name: 
Societal CDMO Inc
Website: 
www.recrocdmo.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree REPH Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts Forecast:
REPH Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding REPH | Societal CDMO Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2024, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.